SCHEMBL10321615

SCHEMBL10321615

COC(=O)c1cccc(NC(=O)c2cc3cnc(OC)cc3[nH]c2=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.50
▸ DYRK1A Q13627 6/20 0.49
▸ DYRK1B Q9Y463 6/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ TP53 P04637 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ GPR17 Q13304 1/20 0.45
▸ CREBBP Q92793 1/20 0.45
▸ ABL1 P00519 1/20 0.44
▸ RIN1 Q13671 1/20 0.44
▸ NR4A1 P22736 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ PRMT5 O14744 1/20 0.44
▸ WDR77 Q9BQA1 1/20 0.44
▸ KCNK3 O14649 1/20 0.43
▸ KCNK9 Q9NPC2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10330656 0.83 GPR17 (0.54) RAB9ADYRK1ADYRK1BSMN1; SMN2TP53
SCHEMBL10321271 0.83 DYRK1A (0.72) DYRK1ADYRK1BALDH1A1MAPT
SCHEMBL10322245 0.82 DYRK1A (0.72) DYRK1ADYRK1B
SCHEMBL10322342 0.82 POLB (0.47) RAB9ADYRK1ADYRK1BALDH1A1CREBBP
SCHEMBL10322470 0.80 RAB9A (0.43) RAB9ADYRK1ADYRK1BSMN1; SMN2TP53
SCHEMBL10321163 0.80 DYRK1A (0.42) DYRK1ADYRK1BALDH1A1HPGDL3MBTL1
SCHEMBL10446504 0.79 DYRK1A (0.53) RAB9ADYRK1ADYRK1BSMN1; SMN2TP53
SCHEMBL11333469 0.79 DYRK1A (0.60) RAB9ADYRK1ADYRK1BSMN1; SMN2TP53
SCHEMBL10322550 0.77 RAB9A (0.41) RAB9ADYRK1ADYRK1BSMN1; SMN2TP53
SCHEMBL10321742 0.75 DYRK1A (0.61) DYRK1ADYRK1BALDH1A1TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES PSEN1, BRCA1, PSEN2 RAB9A 559/4885DYRK1A 1366/4885DYRK1B 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback